| Literature DB >> 31291871 |
Caroline Amaral Machado1, Ana Cristina Simões e Silva2, Amanda Silva de Miranda3, Thiago Macedo E Cordeiro2, Rodrigo Novaes Ferreira1, Leonardo Cruz de Souza2, Antônio Lúcio Teixeira4, Aline Silva de Miranda1.
Abstract
Traumatic brain injury (TBI) is a major public health problem. It is the leading cause of death and disability, especially among children and young adults. The neurobiology basis underlying TBI pathophysiology remains to be fully revealed. Over the past years, emerging evidence has supported the hypothesis that TBI is an inflammatory based condition, paving the way for the development of potential therapeutic targets. There is no treatment capable to prevent or minimize TBI-associated outcomes. Therefore, the search for effective therapies is a priority goal. In this context, animal models have become valuable tools to study molecular and cellular mechanisms involved in TBI pathogenesis as well as novel treatments. Herein, we discuss therapeutic strategies to treat TBI focused on immunomodulatory and/or anti-inflammatory approaches in the pre-clinical setting. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Immunomodulatory Agents; Inflammation; ; Traumatic Brain Injury; ; Treatment;
Year: 2019 PMID: 31291871 DOI: 10.2174/0929867326666190710173234
Source DB: PubMed Journal: Curr Med Chem ISSN: 0929-8673 Impact factor: 4.530